Methods for enhancing immune responsiveness in an individual toward a target cancer cell population comprising apoptotic cells

Patent metadata

Field	Value
Publication number	US-10934331-B2
Application number	US-201716324240-A
Country	US
Kind code	B2
Filing date	Aug 4, 2017
Priority date	Aug 12, 2016
Publication date	Mar 2, 2021
Grant date	Mar 2, 2021

Abstract

Cell loss by apoptosis is a common feature in certain conditions, including cancer. Dying tumor cells induce immune tolerance within the tumor microenvironment largely through highly conserved homeostatic clearance programs that are designed to restore tissue homeostasis and contribute to the formation of an immunosuppressive niche. The translocation of phosphatidylserine (PS) on cellular membranes, during the initial phases of apoptosis, functions as a recognition and removal signal that limits the immunogenicity of cell death. To remove inhibitory signals in the homeostatic clearance pathway a fusion protein comprising a phosphatidylserine binding domain and an immunostimulatory domain can restore immune responses to dead tumor cells in antigen cross presentation assays and promotes recruitment and retention of tumor antigen specific immune effector cells into tumors. These effects combine to elicit anti-tumor immunity, improve responses to immune checkpoint inhibitors, and enhance the effectiveness of adoptive T cell transfers using engineered T cells.

First claim

What is claimed is:

1. A method of enhancing immune responsiveness in an individual toward a targeted cancer cell population comprising apoptotic cells, the method comprising:
administering a cell, comprising a polynucleotide encoding a phosphatidylserine tether protein, comprising: (i) a phosphatidylserine (PS) binding domain of a TIM family protein or MFG-E8 joined to (ii) an immunomodulatory receptor present on an antigen presenting cell, in a dose effective to increase immune responsiveness to the targeted cell population.

2. The method of claim 1 , wherein the targeted cell population is a cancer cell population.

3. The method of claim 1 , further comprising administering a second therapy to increases apoptosis of the targeted cell population.

4. The method of claim 1 , further comprising administering a second therapy to increase immune responsiveness.

5. The method of claim 4 , wherein the second therapy comprises administration of an immune checkpoint inhibitor.

6. The method of claim 4 , wherein the second therapy comprises administration of a tumor: specific antibody.

7. The method of claim 4 , wherein the second therapy comprises administration of an immune costimulatory molecule agonist.

8. A method of enhancing immune responsiveness in an individual toward a targeted cancer cell population comprising apoptotic cells, the method comprising:
administering a cell, comprising a polynucleotide encoding a phosphatidylserine tether protein, comprising: ((i) a phosphatidylserine (PS) binding domain of Tim-4, Tim-1, or MFG-E8 joined to (ii) an Fc region of a human immunoglobulin, in a dose effective to increase immune responsiveness to the targeted cell population.

9. The method of claim 8 , wherein the Fc region is the Fc region of human IgG1.

10. The method of claim 8 , wherein the phosphatidylserine (PS) binding domain and Fc region are joined by a polypeptide linker.

11. The method of claim 8 , wherein the protein has a sequence of SEQ ID NO:1, 2 or 3.

Assignees

• Univ Leland Stanford Junior

Inventors

• Corey Daniel Mark
• Ring Aaron Michael
• Mccracken Melissa N
• Weissman Irving L

Classifications

• C07K14/62 Primary

  Insulins · CPC title

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/42

  Cancer antigens · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title